Review



primary antibodies against phosphorylated egfr (pegfr)  (Cell Signaling Technology Inc)


Bioz Verified Symbol Cell Signaling Technology Inc is a verified supplier
Bioz Manufacturer Symbol Cell Signaling Technology Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    Cell Signaling Technology Inc primary antibodies against phosphorylated egfr (pegfr)
    Immunohistochemical staining of EGF, <t>pEGFR,</t> TGF-β1 and pSmad3 in LF tissue. A EGF, pEGFR, TGF-β1 and pSmad3 in the LSCS group and Non-LSCS group. B Statistical analysis of EGF, pEGFR, TGF-β1 and pSmad3 levels. The scale bar indicates 50 μm, **** indicates P<0.0001.
    Primary Antibodies Against Phosphorylated Egfr (Pegfr), supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/primary antibodies against phosphorylated egfr (pegfr)/product/Cell Signaling Technology Inc
    Average 90 stars, based on 1 article reviews
    primary antibodies against phosphorylated egfr (pegfr) - by Bioz Stars, 2026-03
    90/100 stars

    Images

    1) Product Images from "EGF Contributes to Hypertrophy of Human Ligamentum Flavum via the TGF-β1/Smad3 Signaling Pathway"

    Article Title: EGF Contributes to Hypertrophy of Human Ligamentum Flavum via the TGF-β1/Smad3 Signaling Pathway

    Journal: International Journal of Medical Sciences

    doi: 10.7150/ijms.76077

    Immunohistochemical staining of EGF, pEGFR, TGF-β1 and pSmad3 in LF tissue. A EGF, pEGFR, TGF-β1 and pSmad3 in the LSCS group and Non-LSCS group. B Statistical analysis of EGF, pEGFR, TGF-β1 and pSmad3 levels. The scale bar indicates 50 μm, **** indicates P<0.0001.
    Figure Legend Snippet: Immunohistochemical staining of EGF, pEGFR, TGF-β1 and pSmad3 in LF tissue. A EGF, pEGFR, TGF-β1 and pSmad3 in the LSCS group and Non-LSCS group. B Statistical analysis of EGF, pEGFR, TGF-β1 and pSmad3 levels. The scale bar indicates 50 μm, **** indicates P<0.0001.

    Techniques Used: Immunohistochemical staining, Staining

    Protein expression levels of EGF, pEGFR, EGFR, TGF-β1, pSmad3, Smad3, collagen I and collagen III in LF tissue. The levels of EGF, pEGFR, TGF-β1, pSmad3, collagen I and collagen III in the LSCS group were significantly higher than those in Non-LSCS group. The level of phosphorylated EGFR represents the degree of EGFR activation. When the level of total EGFR is unchanged and the level of phosphorylated EGFR is decreased, it indicates that EGFR activation is decreased or inhibited, and vice versa. Likewise, the level of phosphorylated Smad3 represents the degree of Smad3 activity.
    Figure Legend Snippet: Protein expression levels of EGF, pEGFR, EGFR, TGF-β1, pSmad3, Smad3, collagen I and collagen III in LF tissue. The levels of EGF, pEGFR, TGF-β1, pSmad3, collagen I and collagen III in the LSCS group were significantly higher than those in Non-LSCS group. The level of phosphorylated EGFR represents the degree of EGFR activation. When the level of total EGFR is unchanged and the level of phosphorylated EGFR is decreased, it indicates that EGFR activation is decreased or inhibited, and vice versa. Likewise, the level of phosphorylated Smad3 represents the degree of Smad3 activity.

    Techniques Used: Expressing, Activation Assay, Activity Assay

    Protein expression levels of pEGFR, EGFR, TGF-β1, pSmad3, Smad3, collagen I and collagen III in LF cells after exposure to different concentrations of exogenous EGF with or without the EGFR inhibitor erlotinib. Expression of pEGFR, TGF-β1, pSmad3, collagen I and collagen III in ligamentum flavum cells was significantly increased in a dose-dependent manner after exposed to various concentrations of exogenous EGF without erlotinib, erlotinib significantly attenuated EGF-induced increases in pEGFR, TGF-β1 pSmad3, collagen I and collagen III expression.
    Figure Legend Snippet: Protein expression levels of pEGFR, EGFR, TGF-β1, pSmad3, Smad3, collagen I and collagen III in LF cells after exposure to different concentrations of exogenous EGF with or without the EGFR inhibitor erlotinib. Expression of pEGFR, TGF-β1, pSmad3, collagen I and collagen III in ligamentum flavum cells was significantly increased in a dose-dependent manner after exposed to various concentrations of exogenous EGF without erlotinib, erlotinib significantly attenuated EGF-induced increases in pEGFR, TGF-β1 pSmad3, collagen I and collagen III expression.

    Techniques Used: Expressing



    Similar Products

    primary antibodies against phosphorylated egfr (pegfr)  (Cell Signaling Technology Inc)
    90
    Cell Signaling Technology Inc primary antibodies against phosphorylated egfr (pegfr)
    Immunohistochemical staining of EGF, <t>pEGFR,</t> TGF-β1 and pSmad3 in LF tissue. A EGF, pEGFR, TGF-β1 and pSmad3 in the LSCS group and Non-LSCS group. B Statistical analysis of EGF, pEGFR, TGF-β1 and pSmad3 levels. The scale bar indicates 50 μm, **** indicates P<0.0001.
    Primary Antibodies Against Phosphorylated Egfr (Pegfr), supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/primary antibodies against phosphorylated egfr (pegfr)/product/Cell Signaling Technology Inc
    Average 90 stars, based on 1 article reviews
    primary antibodies against phosphorylated egfr (pegfr) - by Bioz Stars, 2026-03
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Immunohistochemical staining of EGF, pEGFR, TGF-β1 and pSmad3 in LF tissue. A EGF, pEGFR, TGF-β1 and pSmad3 in the LSCS group and Non-LSCS group. B Statistical analysis of EGF, pEGFR, TGF-β1 and pSmad3 levels. The scale bar indicates 50 μm, **** indicates P<0.0001.

    Journal: International Journal of Medical Sciences

    Article Title: EGF Contributes to Hypertrophy of Human Ligamentum Flavum via the TGF-β1/Smad3 Signaling Pathway

    doi: 10.7150/ijms.76077

    Figure Lengend Snippet: Immunohistochemical staining of EGF, pEGFR, TGF-β1 and pSmad3 in LF tissue. A EGF, pEGFR, TGF-β1 and pSmad3 in the LSCS group and Non-LSCS group. B Statistical analysis of EGF, pEGFR, TGF-β1 and pSmad3 levels. The scale bar indicates 50 μm, **** indicates P<0.0001.

    Article Snippet: After antigen retrieval and blocking treatment, primary antibodies against EGF (1: 200, Abcam, Cambridge, UK), phosphorylated EGFR (pEGFR) (1: 100, Cell Signaling Technology, Danvers, MA), TGF-β1(1: 100, Abcam), phosphorylated Smad3 (pSmad3) (1: 200, Cell Signaling Technology, Danvers, MA), collagen I (1: 100, Abcam), and collagen III (1: 100, Abcam) were applied overnight at 4°C.

    Techniques: Immunohistochemical staining, Staining

    Protein expression levels of EGF, pEGFR, EGFR, TGF-β1, pSmad3, Smad3, collagen I and collagen III in LF tissue. The levels of EGF, pEGFR, TGF-β1, pSmad3, collagen I and collagen III in the LSCS group were significantly higher than those in Non-LSCS group. The level of phosphorylated EGFR represents the degree of EGFR activation. When the level of total EGFR is unchanged and the level of phosphorylated EGFR is decreased, it indicates that EGFR activation is decreased or inhibited, and vice versa. Likewise, the level of phosphorylated Smad3 represents the degree of Smad3 activity.

    Journal: International Journal of Medical Sciences

    Article Title: EGF Contributes to Hypertrophy of Human Ligamentum Flavum via the TGF-β1/Smad3 Signaling Pathway

    doi: 10.7150/ijms.76077

    Figure Lengend Snippet: Protein expression levels of EGF, pEGFR, EGFR, TGF-β1, pSmad3, Smad3, collagen I and collagen III in LF tissue. The levels of EGF, pEGFR, TGF-β1, pSmad3, collagen I and collagen III in the LSCS group were significantly higher than those in Non-LSCS group. The level of phosphorylated EGFR represents the degree of EGFR activation. When the level of total EGFR is unchanged and the level of phosphorylated EGFR is decreased, it indicates that EGFR activation is decreased or inhibited, and vice versa. Likewise, the level of phosphorylated Smad3 represents the degree of Smad3 activity.

    Article Snippet: After antigen retrieval and blocking treatment, primary antibodies against EGF (1: 200, Abcam, Cambridge, UK), phosphorylated EGFR (pEGFR) (1: 100, Cell Signaling Technology, Danvers, MA), TGF-β1(1: 100, Abcam), phosphorylated Smad3 (pSmad3) (1: 200, Cell Signaling Technology, Danvers, MA), collagen I (1: 100, Abcam), and collagen III (1: 100, Abcam) were applied overnight at 4°C.

    Techniques: Expressing, Activation Assay, Activity Assay

    Protein expression levels of pEGFR, EGFR, TGF-β1, pSmad3, Smad3, collagen I and collagen III in LF cells after exposure to different concentrations of exogenous EGF with or without the EGFR inhibitor erlotinib. Expression of pEGFR, TGF-β1, pSmad3, collagen I and collagen III in ligamentum flavum cells was significantly increased in a dose-dependent manner after exposed to various concentrations of exogenous EGF without erlotinib, erlotinib significantly attenuated EGF-induced increases in pEGFR, TGF-β1 pSmad3, collagen I and collagen III expression.

    Journal: International Journal of Medical Sciences

    Article Title: EGF Contributes to Hypertrophy of Human Ligamentum Flavum via the TGF-β1/Smad3 Signaling Pathway

    doi: 10.7150/ijms.76077

    Figure Lengend Snippet: Protein expression levels of pEGFR, EGFR, TGF-β1, pSmad3, Smad3, collagen I and collagen III in LF cells after exposure to different concentrations of exogenous EGF with or without the EGFR inhibitor erlotinib. Expression of pEGFR, TGF-β1, pSmad3, collagen I and collagen III in ligamentum flavum cells was significantly increased in a dose-dependent manner after exposed to various concentrations of exogenous EGF without erlotinib, erlotinib significantly attenuated EGF-induced increases in pEGFR, TGF-β1 pSmad3, collagen I and collagen III expression.

    Article Snippet: After antigen retrieval and blocking treatment, primary antibodies against EGF (1: 200, Abcam, Cambridge, UK), phosphorylated EGFR (pEGFR) (1: 100, Cell Signaling Technology, Danvers, MA), TGF-β1(1: 100, Abcam), phosphorylated Smad3 (pSmad3) (1: 200, Cell Signaling Technology, Danvers, MA), collagen I (1: 100, Abcam), and collagen III (1: 100, Abcam) were applied overnight at 4°C.

    Techniques: Expressing